Potential value of expression of receptor accessory protein 4 for evaluating the prognosis of lower-grade glioma patients
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Receptor Expression Enhancing Protein 4 (REEP4) is elevated in lower grade glioma (LGG), correlating with poor survival. This study highlights REEP4 as a potential biomarker and therapeutic target in LGG.
Area Of Science
- Oncology
- Molecular Biology
- Genomics
Background
- Receptor Expression Enhancing Protein 4 (REEP4) regulates mitosis, a process often aberrant in lower grade glioma (LGG).
- No prior studies have investigated the role of REEP4 in LGG pathogenesis.
Purpose Of The Study
- To investigate the role and potential of REEP4 as a biomarker and therapeutic target in lower grade glioma (LGG).
Main Methods
- Analysis of transcriptome and DNA methylation data from thousands of LGG patients.
- Utilized big data analysis and molecular biology experiments to assess REEP4's impact on LGG.
Main Results
- REEP4 expression is significantly elevated in LGG and negatively regulated by methylation at cg16311504.
- High REEP4 expression and low cg16311504 methylation correlate with reduced patient survival.
- REEP4 influences cell cycle, MAPK, and NOD-like receptor signaling pathways, and increases immune cell infiltration and PD-L1 expression in the LGG tumor microenvironment.
Conclusions
- REEP4 is identified as an independent risk factor in LGG progression.
- REEP4 shows potential as a novel therapeutic target for anti-tumor treatment in LGG.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.